Patient characteristics help predict individual response to treatment with natalizumab vs fingolimod in relapsing-remitting MS
Francesca Bovis, Noemi Montobbio,Dana Horakova,Eva Havrdova,Serkan Ozakbas,Francesco Patti,Raed Alroughani,Guillermo Izquierdo, Sara Eichau Madueno,Katherine Buzzard,Olga Skibina,Rana Karabudak,Alessandra Lugaresi,Marco Onofrj,Murat Terzi,Cavit Boz,Pierre Grammond,Alexandre Prat,Marc Girard,Pierre Duquette,Bassem Yamout,Samia Khoury,Anneke Van der Walt,Helmut Butzkueven,Jeannette Lechner-Scott,Michael Barnett,Suzanne Hodgkinson,Richard Macdonell,Davide Maimone, O. Gerlach,Riadh Gouider,Saloua Mrabet, Maria Jose, Pontes Marques Sa,Bianca Weinstock-Guttman,Pamela Mccombe,Bart Van Wijmeersch,Julie Prevost,Mark Slee,Aysun Soysal,Vahid Shaygannejad,Nevin A. John,Tunde Csepany,Daniele Spitaleri, Eduardo Aguera Morales,Claudio Marcello Solaro,Recai Turkoglu,Maria Pia Amato, Cristina Ramo Tello,Vincent Van Pesch,Matteo Foschi,Tomas Kalincik,Maria Pia Sormani MULTIPLE SCLEROSIS JOURNAL(2023)
AI 理解论文
溯源树
样例